NASDAQ:KYMR

Kymera Therapeutics Stock Earnings Reports

etoro logo Buy KYMR
*Your capital is at risk
$73.21
+1.92 (+2.69%)
At Close: Jun 03, 2026

Kymera Therapeutics Earnings Calls

Mar 31, 2026
-$0.710 (20.22%)
Release date Apr 30, 2026
EPS estimate -$0.89
EPS actual -$0.710
EPS Surprise 20.22%
Revenue estimate 8.267M
Revenue actual 34.365M
Revenue Surprise 315.71%
Dec 31, 2025
-$0.97 (-23.78%)
Release date Feb 26, 2026
EPS estimate -$0.784
EPS actual -$0.97
EPS Surprise -23.78%
Revenue estimate 15.048M
Revenue actual 2.871M
Revenue Surprise -80.92%
Sep 30, 2025
-$0.90 (-26.76%)
Release date Nov 04, 2025
EPS estimate -$0.710
EPS actual -$0.90
EPS Surprise -26.76%
Revenue estimate 14.452M
Revenue actual 2.764M
Revenue Surprise -80.87%
Jun 30, 2025
-$0.95 (-14.46%)
Release date Aug 11, 2025
EPS estimate -$0.83
EPS actual -$0.95
EPS Surprise -14.46%
Revenue estimate 17.131M
Revenue actual 11.476M
Revenue Surprise -33.01%

Last 4 Quarters for Kymera Therapeutics

Below you can see how KYMR performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

SIGN UP FREE
or
Creating an account or logging in means you agree to StockInvest.us Terms of Use and Privacy Policy.
Jun 30, 2025 Missed
Release date Aug 11, 2025
Price on release $37.68
EPS estimate -$0.83
EPS actual -$0.95
EPS surprise -14.46%
Date Price
Aug 05, 2025 $42.97
Aug 06, 2025 $41.35
Aug 07, 2025 $40.85
Aug 08, 2025 $40.62
Aug 11, 2025 $37.68
Aug 12, 2025 $39.87
Aug 13, 2025 $40.73
Aug 14, 2025 $41.55
Aug 15, 2025 $42.63
4 days before -12.31%
4 days after 13.14%
On release day 5.81%
Change in period -0.791%
Sep 30, 2025 Missed
Release date Nov 04, 2025
Price on release $59.91
EPS estimate -$0.710
EPS actual -$0.90
EPS surprise -26.76%
Date Price
Oct 29, 2025 $60.03
Oct 30, 2025 $61.44
Oct 31, 2025 $61.84
Nov 03, 2025 $59.72
Nov 04, 2025 $59.91
Nov 05, 2025 $59.89
Nov 06, 2025 $61.00
Nov 07, 2025 $58.66
Nov 10, 2025 $61.26
4 days before -0.200%
4 days after 2.25%
On release day -0.0334%
Change in period 2.05%
Dec 31, 2025 Missed
Release date Feb 26, 2026
Price on release $95.03
EPS estimate -$0.784
EPS actual -$0.97
EPS surprise -23.78%
Date Price
Feb 20, 2026 $87.40
Feb 23, 2026 $88.43
Feb 24, 2026 $91.01
Feb 25, 2026 $90.68
Feb 26, 2026 $95.03
Feb 27, 2026 $91.35
Mar 02, 2026 $90.10
Mar 03, 2026 $86.35
Mar 04, 2026 $86.11
4 days before 8.73%
4 days after -9.39%
On release day -3.87%
Change in period -1.48%
Mar 31, 2026 Beat
Release date Apr 30, 2026
Price on release $81.07
EPS estimate -$0.89
EPS actual -$0.710
EPS surprise 20.22%
Date Price
Apr 24, 2026 $84.91
Apr 27, 2026 $86.68
Apr 28, 2026 $83.85
Apr 29, 2026 $81.51
Apr 30, 2026 $81.07
May 01, 2026 $80.71
May 04, 2026 $83.59
May 05, 2026 $82.71
May 06, 2026 $86.26
4 days before -4.52%
4 days after 6.40%
On release day -0.444%
Change in period 1.59%

Kymera Therapeutics Earnings History

Earnings Calendar

FAQ

When is the earnings report for KYMR?
Kymera Therapeutics Inc. (KYMR) has scheduled its earnings report for Aug 10, 2026 before the markets open.

What is the KYMR price-to-earnings (P/E) ratio?
KYMR P/E ratio as of Jun 03, 2026 (TTM) is -22.07.

What is the KYMR EPS forecast?
The forecasted EPS (Earnings Per Share) for Kymera Therapeutics Inc. (KYMR) for the first fiscal quarter 2026 is -$0.700.

What are Kymera Therapeutics Inc.'s retained earnings?
On its balance sheet, Kymera Therapeutics Inc. reported retained earnings of $34.37 million for the latest quarter ending Mar 31, 2026.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
ABOUT KYMERA THERAPEUTICS INC.
Kymera Therapeutics
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation ...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE